Vancouver, British Columbia–(Newsfile Corp. – May 5, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: “1XU1”) (“ Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market (“OTCQB”) effective May 5, 2021. “We are thrilled to be up…


Previous articleRed Light Holland Receives Patent Pending Status For ‘Find Your Dose’ Customization of Microdosing Kits Based on Biometric and Movement Data
Next articleCan Psychedelics Provide Relief for Autistic Individuals?